| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2014/038 | ||
|---|---|---|---|
| Date of filing | 07/07/2014 | ||
| Notification of Application Published | 30/07/2014 | ||
| Status | Rejected | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
ASTRAZENECA AB SE-151 85 Södertälje SWEDEN |
||
| Patent Number | 1506211 | ||
| Title of Invention | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | ||
| Date of Expiry of Patent | 14/05/2023 | ||
| Product Type | Medicinal Product | ||
| Product Identity | A combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin and pharmaceutically acceptable salts thereof as a protected by basic patent EP1506211 B1 | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/13/900/001-005 | ||
| Authorisation Date | 16/01/2014 | ||
| Identity of Product Authorised | Xigduo - dapagliflozin/metformin | ||
| Address for Service |
FRKelly 27 Clyde Road Ballsbridge Dublin 4 D04 F838 IRELAND |
||
| Renewal Fees | |||
| 08/07/2014 | Request for grant a Supplementary Protection Certificate filed on 07/07/2014, numbered 2014/038. | ||
| 11/07/2014 | Amend Request for grant, filed on 09/07/2014. Product definition in Section 5 amended from A combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin and pharmaceutically salts thereof as a protected by basic patent EP1506211 B1 to A combination of dapagliflozin or a pharmaceutically acceptable salt thereof and metformin and pharmaceutically acceptable salts thereof as a protected by basic patent EP1506211 B1 | ||
| 21/06/2021 | Request for grant of Supplementary Protection Certification No. 2014/038 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
| 05/11/2021 | Appeal against decision of the Controller filed in the High Court on 20 October 2021 [Record No. 2021/184 Sp] | ||